https://digital.nhs.uk/data-and-information/publications/statistical/nhs-dental-statistics<\/a><\/p>A further suite of management information is not routinely published but is directly shared with dental contract holders through the IT system used to manage remuneration known as Compass. Other data held by the NHS Business Services Authority is available by specific request subject to the usual rules on data protection.<\/p>
Oversight of the NHS Business Services Authority overall is provided by the Department. The NHS Business Services Authority dental services carry out yearly research into user satisfaction with its services. This includes a survey of dental contract holders. The survey aims to identify areas for further improvement and the results are shared with the Department.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "255314"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-05-21T16:15:59.277Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Dental Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, for what reasons the statistics compiled by the NHS Business Services Authority are not shared in full with dental practice owners.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
, "tablingMemberPrinted" : [{"_value" : "Diana Johnson"}
], "uin" : "255313"}
, {"_about" : "http://data.parliament.uk/resources/1127214", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1127214/answer", "answerText" : {"_value" : "
The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.<\/p>
<\/p>
The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "255381"}
, {"_value" : "255382"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-05-21T16:12:54.06Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Drugs: Prices"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies, if the Government will withdraw its support for suggested amendments to remove every mention of high prices.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4651", "label" : {"_value" : "Biography information for Dan Carden"}
}
, "tablingMemberConstituency" : {"_value" : "Liverpool, Walton"}
, "tablingMemberPrinted" : [{"_value" : "Dan Carden"}
], "uin" : "255380"}
, {"_about" : "http://data.parliament.uk/resources/1127215", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1127215/answer", "answerText" : {"_value" : "
The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.<\/p>
<\/p>
The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "255380"}
, {"_value" : "255382"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-05-21T16:12:54.12Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Drugs: Prices"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies, if the Government will take steps to help ensure that the recommendation to member states calls for mandatory rather than voluntary measures.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4651", "label" : {"_value" : "Biography information for Dan Carden"}
}
, "tablingMemberConstituency" : {"_value" : "Liverpool, Walton"}
, "tablingMemberPrinted" : [{"_value" : "Dan Carden"}
], "uin" : "255381"}
, {"_about" : "http://data.parliament.uk/resources/1127216", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1127216/answer", "answerText" : {"_value" : "
The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.<\/p>
<\/p>
The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "255380"}
, {"_value" : "255381"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-05-21T16:12:54.153Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Drugs: Prices"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if the Government will support the draft resolution for consideration by the World Health Assembly in May 2019 on improving the transparency of markets for medicines, vaccines and other health-related technologies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4651", "label" : {"_value" : "Biography information for Dan Carden"}
}
, "tablingMemberConstituency" : {"_value" : "Liverpool, Walton"}
, "tablingMemberPrinted" : [{"_value" : "Dan Carden"}
], "uin" : "255382"}
, {"_about" : "http://data.parliament.uk/resources/1126459", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1126459/answer", "answerText" : {"_value" : "
It is right that these decisions are clinically led. As for any other medical treatment, if two clinicians are of the opinion that, on balance, it is not in the best interest of the patient to prescribe a cannabis-based product, then it will not be prescribed.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-05-21T10:45:44.23Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what the process will be for patients that are refused a prescription for medical cannabis oil by their second opinion; and will he make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"}
}
, "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"}
, "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"}
], "uin" : "254164"}
, {"_about" : "http://data.parliament.uk/resources/1126508", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1126508/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) and NHS England are leading the dialogue with Vertex Pharmaceuticals on access to their portfolio of cystic fibrosis medicines, including Orkambi and Symkevi.<\/p>
NHS England has proposed an offer that would represent the largest ever commitment of its kind in the history of the National Health Service - in the region of £500 million over five years - and would provide immediate access for patients to all Vertex licensed medicines in advance of assessment by NICE. The Government fully supports the approach that NICE and NHS England are adopting. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the NHS.<\/p>
My Rt. hon. Friend the Secretary of State for Health and Social Care held a meeting on 11 March with all the parties to discuss how best to reach a deal so that people with cystic fibrosis and their families can benefit as soon as possible. Vertex, NICE and NHS England subsequently met on Thursday 21 March and have agreed to continue discussions.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-05-20", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-05-20T16:00:42.25Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cystic Fibrosis: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent progress has been made on making (a) Orkambi and (b) Symkevi available on the NHS for people diagnosed with cystic fibrosis; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
], "uin" : "254113"}
, {"_about" : "http://data.parliament.uk/resources/1126597", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1126597/answer", "answerText" : {"_value" : "
Local clinical commissioning groups (CCGs), with their clinical expertise, are responsible for commissioning high-quality care to meet the needs of their populations. CCGs are required to carefully consider the National Institute for Health and Care Excellence guidelines in making commissioning decisions. These are available at the following link:<\/p>
https://www.nice.org.uk/guidance/ng77<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-05-21T10:44:28.927Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cataracts: Surgery"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that cataract removal surgery is available to everyone who would benefit from it.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/312", "label" : {"_value" : "Biography information for Dame Caroline Spelman"}
}
, "tablingMemberConstituency" : {"_value" : "Meriden"}
, "tablingMemberPrinted" : [{"_value" : "Dame Caroline Spelman"}
], "uin" : "254121"}
, {"_about" : "http://data.parliament.uk/resources/1126678", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1126678/answer", "answerText" : {"_value" : "A revised version of the FP10 prescription form, featuring a dedicated tick-box for use by Universal Credit claimants who meet the criteria for free National Health Service prescriptions, recently received Ministerial clearance.<\/p>
<\/p>
Any change involves major system and software updates across the NHS to allow the re-designed form to be used and processed. The revised paper form is currently being prepared for testing, to ensure it is compatible with the scanners used by the NHS Business Services Authority.<\/p>
<\/p>
The revised form will be introduced at the earliest opportunity.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-05-20", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-05-20T15:59:00.733Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prescriptions: Universal Credit"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what the timeframe is for NHS prescription forms to be amended to include tick boxes for universal credit.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/478", "label" : {"_value" : "Biography information for Lord Field of Birkenhead"}
}
, "tablingMemberConstituency" : {"_value" : "Birkenhead"}
, "tablingMemberPrinted" : [{"_value" : "Frank Field"}
], "uin" : "254153"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answer.answeringMemberConstituency=South+Ribble&max-answer.questionFirstAnswered.=2019-05-21T16%3A15%3A59.277Z", "page" : 0, "startIndex" : 1, "totalResults" : 319, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}